132 results
424B3
KZIA
Kazia Therapeutics Limited
21 Feb 24
Prospectus supplement
4:19pm
I data at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, jointly organized by the Society for Neuro-Oncology … and the American Society for Clinical Oncology, held in Toronto, Canada.
Last year, paxalisib was awarded Fast Track Designation (FTD) on the basis of the Part I
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
21 Feb 24
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
9:19am
and Brain Metastases, jointly organized by the Society for Neuro-Oncology and the American Society for Clinical Oncology, held in Toronto, Canada
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
21 Nov 23
Current report (foreign)
4:09pm
Exhibit 99.1
PRESS RELEASE
21 November 2023
KAZIA PROVIDES OVERVIEW OF PAXALISIB
RELATED PRESENTATIONS FROM THE SOCIETY OF
NEURO-ONCOLOGY 2023 … highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual
6-K
KZIA
Kazia Therapeutics Limited
21 Nov 23
Current report (foreign)
4:09pm
Presentations from the Society of Neuro-Oncology 2023 Annual Meeting” providing highlights from certain clinical and preclinical presentations given … by industry leaders at the Society of Neuro-Oncology 2023 Annual Meeting (“SNO 2023 Meeting”).
Key Paxalisib Highlights from SNO 2023 Meeting
Combining
6-K
KZIA
Kazia Therapeutics Limited
15 Nov 23
Kazia Announces the Release of PNOC022
9:13am
Study Abstract Highlighting Paxalisib Diffuse Midline Glioma Patients Ahead of the Society of Neuro-Oncology 2023 Annual Meeting,” regarding a late … -breaking abstract released by organizers of the Society of Neuro-Oncology 2023 Annual Meeting.
The preliminary results from a single cohort
6-K
EX-99.1
6a2pmw6w ee
15 Nov 23
Kazia Announces the Release of PNOC022
9:13am
6-K
xexy0xwfk2
23 Oct 23
Kazia Therapeutics Announces Clinical Data at Esmo 2023 from Ongoing Phase 1 EVT801 Study
8:30am
6-K
EX-99.1
wc1godg4
23 Oct 23
Kazia Therapeutics Announces Clinical Data at Esmo 2023 from Ongoing Phase 1 EVT801 Study
8:30am
6-K
EX-99.1
r9w4juyji2t fa
29 Sep 23
Kazia Therapeutics Announces Acceptance of
7:00am
6-K
bazq9glcinqypifey72w
29 Sep 23
Kazia Therapeutics Announces Acceptance of
7:00am
6-K
EX-99.1
au6 nnqpg5
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.1
wdlqrv pqu9n6zgtl
6 Jul 23
Current report (foreign)
4:15pm
6-K
EX-99.1
19dmw2muvp1ojw0he9j
27 Oct 22
Current report (foreign)
7:21am
6-K
EX-99.1
ndxe4 uzsrxm948
1 Sep 22
Current report (foreign)
4:07pm
6-K
EX-99.1
4lwh0cpssh kk5
5 Aug 22
Kazia Therapeutics Reports Promising Interim Data from Combination Study of Paxalisib with Radiotherapy In Treatment of Brain Metastases
8:18am
424B5
hiwbdx1x16a5mie
22 Apr 22
Prospectus supplement for primary offering
4:04pm
6-K
8tk2rn
3 Dec 21
Current report (foreign)
6:22am